Trials / Unknown
UnknownNCT03291444
CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS
A Clinical Study of Chimeric Antigen Receptor T Cells Combined With Eps8 Peptide Specific Dendritic Cell for Patients With Relapsed/Refractory Leukemia and Myelodysplastic Syndromes
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Zhujiang Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to verify the safety and potential effectiveness of CART cells combined with peptide specific dendritic cell in relapsed/refractory leukemia.
Detailed description
A prospective study to evaluate the safety and efficacy of Chimeric antigen receptor T cells combined with Eps8 or WT1（Wilms tumor 1） peptide specific dendritic cell for patients with relapsed/refractory leukemia. There are options for CAR-targets: CD19, CD20, CD22 and CD10 for acute lymphoblastic leukemia; CD33, CD38 CD56, CD117, CD123, CD34 and Muc1 for acute myeloid leukemia and Myelodysplastic Syndrome. Progression free survival, overall Survival, overall response rate, and duration of response were monitored.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Chimeric antigen receptor T cells | After pretreatment, chimeric antigen receptor T cells will be transfused. |
| BIOLOGICAL | peptide specific dendritic cell | After transfusion of chimeric antigen receptor T cells, Eps8 or WT1 peptide specific dendritic cell were intradermal injected. |
Timeline
- Start date
- 2018-05-05
- Primary completion
- 2024-12-31
- Completion
- 2025-06-01
- First posted
- 2017-09-25
- Last updated
- 2024-03-15
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03291444. Inclusion in this directory is not an endorsement.